233 related articles for article (PubMed ID: 8785019)
1. A risk-benefit assessment of teicoplanin in the treatment of infections.
de Lalla F; Tramarin A
Drug Saf; 1995 Nov; 13(5):317-28. PubMed ID: 8785019
[TBL] [Abstract][Full Text] [Related]
2. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
3. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
Brogden RN; Peters DH
Drugs; 1994 May; 47(5):823-54. PubMed ID: 7520860
[TBL] [Abstract][Full Text] [Related]
4. Teicoplanin or vancomycin in the treatment of gram-positive infections?
Murphy S; Pinney RJ
J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
[TBL] [Abstract][Full Text] [Related]
5. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
Spencer CM; Bryson HM
Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
[TBL] [Abstract][Full Text] [Related]
6. The comparative efficacy and safety of teicoplanin and vancomycin.
Wood MJ
J Antimicrob Chemother; 1996 Feb; 37(2):209-22. PubMed ID: 8707731
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Campoli-Richards DM; Brogden RN; Faulds D
Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
[TBL] [Abstract][Full Text] [Related]
8. A review of teicoplanin in the treatment of serious neonatal infections.
Fanos V; Kacet N; Mosconi G
Eur J Pediatr; 1997 Jun; 156(6):423-7. PubMed ID: 9208233
[TBL] [Abstract][Full Text] [Related]
9. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
Zeckel ML
J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
[TBL] [Abstract][Full Text] [Related]
10. Teicoplanin.
Shea KW; Cunha BA
Med Clin North Am; 1995 Jul; 79(4):833-44. PubMed ID: 7791426
[TBL] [Abstract][Full Text] [Related]
11. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
Chow AW; Jewesson PJ; Kureishi A; Phillips GL
Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of teicoplanin and vancomycin.
Wilson AP
Int J Antimicrob Agents; 1998 May; 10(2):143-52. PubMed ID: 9716291
[TBL] [Abstract][Full Text] [Related]
15. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
Svetitsky S; Leibovici L; Paul M
Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin].
Paganini H; Marin M
Medicina (B Aires); 2002; 62 Suppl 2():52-5. PubMed ID: 12481490
[TBL] [Abstract][Full Text] [Related]
18. Infective endocarditis and glycopeptides.
Pittet D; Harding I
J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
[TBL] [Abstract][Full Text] [Related]
19. [The use of teicoplanin in neutropenic patients: values and limits].
Espinouse D; Chomarat M
Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
[TBL] [Abstract][Full Text] [Related]
20. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
